“Anemia and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients”

Danzinger, Sabine; Fügerl, Alexandra; Pfeifer, Christian; Bernathova, Maria; Tendl-Schulz, Kristina; Seifert, Michael

doi:10.1080/07357907.2021.1928166

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding to chemotherapy induced anemia (CIA), unfavorable in uences were emerged along with treatment. A tendency of lower median tumor response was found in breast cancer patients with CIA [13]. Moreover, the 5-year overall survival are lower in OS patients with continuous decrease in haemoglobin(> 7.6 g/L) during chemotherapy [14].…”

Section: Introductionmentioning

confidence: 94%

Anemia can predict prognosis and response to neoadjuvant chemotherapy in osteosarcoma at pre-operative stage: a retrospective analysis

Wang

Sun

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose Anemia is relatively common in cancer patients, and is associated with poor survival in patients with various malignancies. However, how anemia would affect prognosis and response to neoadjuvant chemotherapy(NAC) in osteosarcoma(OS) is still without substantial evidence. Methods We retrospectively analyzed 256 OS patients who underwent standard NAC in our institute. Hb concentrations before/after NAC and changed Hb levels (dHb, Hb level before NAC minus that after NAC) were recorded to assess their prognostic value in DFS(disease-free survival) and tumor necrosis rate to NAC. Results There was higher percentage of pretreatment anemia in poor response group(87 out of 181) with a tumor necrosis rate < 90%, compared with those in good response group(36 out of 75). Besides, in patients with good response to NAC, the median dHb was 13, which was smaller than that(median dHb 18) in poor response to NAC. Further ROC analysis demonstrated that dHb had a significant role in prediction for the NAC response in OS patients.In survival analysis, patients with high dHb(≥ 12.5) had an inferior DFS(38 ± 2.44 months), compared with those with dHb below 12.5(47 ± 7.26 months). Conclusion In osteosarcoma, dynamic Hb decrease after NAC predicted poor survival and worse response to neoadjuvant chemotherapy. Pretreatment anemia might be a potential indicator to forecast response to NAC. Attempts to correct anemia and their effects on outcomes for osteosarcoma patients should be explored in future studies.

show abstract

Section: Introductionmentioning

confidence: 94%

Anemia can predict prognosis and response to neoadjuvant chemotherapy in osteosarcoma at pre-operative stage: a retrospective analysis

Wang

Sun

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Regarding to chemotherapy induced anemia (CIA), unfavorable influences were emerged along with treatment. A tendency of lower median tumor response was found in breast cancer patients with CIA [ 13 ]. Moreover, the 5-year overall survival are lower in OS patients with continuous decrease in haemoglobin (> 7.6 g/L) during chemotherapy [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients

Yu,

Sun,

Wang

et al. 2024

Support Care Cancer

View full text Add to dashboard Cite

Purpose Anemia is relatively common in cancer patients, and is associated with poor survival in patients with various malignancies. However, how anemia would affect prognosis and response to neoadjuvant chemotherapy (NAC) in osteosarcoma (OS) is still without substantial evidence. Methods We retrospectively analysed 242 patients with stage II OS around the knee joint in our institute. Changed hemoglobin (Hb) levels (before and after NAC) were recorded to assess the prognostic value in DFS (disease-free survival) and tumor response to NAC. Univariate and multivariate analyses were conducted to identify prognostic factors related with outcome in OS patients. Results The mean Hb level significantly decreased after NAC (134.5 ± 15.3 g/L vs. 117.4 ± 16.3 g/L). The percentage of mild (21%), moderate (4.2%) and severe (0%) anemia patients markedly increased after NAC: 41%, 24% and 4.1% respectively. There was higher percentage of ≥ 5% Hb decline in patients with tumor necrosis rate < 90% (141 out of 161), compared with those with tumor necrosis rate ≥ 90% (59 out of 81). Further univariate and survival analysis demonstrated that Hb decline had a significant role in prediction survival in OS patients. Patients with ≥ 5% Hb decline after NAC had an inferior DFS compared with those with < 5% Hb decline. Conclusion In osteosarcoma, patients with greater Hb decrease during neoadjuvant treatment were shown to have worse DFS and a poorer response to NAC than those without. Attempts to correct anemia and their effects on outcomes for osteosarcoma patients should be explored in future studies.

show abstract

“Anemia and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients”

Cited by 2 publications

References 38 publications

Anemia can predict prognosis and response to neoadjuvant chemotherapy in osteosarcoma at pre-operative stage: a retrospective analysis

Anemia can predict prognosis and response to neoadjuvant chemotherapy in osteosarcoma at pre-operative stage: a retrospective analysis

Neoadjuvant chemotherapy-induced hemoglobin decline as a prognostic factor in osteosarcoma around the knee joint: a single-center retrospective analysis of 242 patients

Contact Info

Product

Resources

About